Multiple Myeloma Treatment Strategies with Novel Agents in 2011: A European Perspective

H Ludwig; M Beksac; J Blade; J Cavenagh; M Cavo; M Delforge; M Dimopoulos; J Drach; H Einsele; T Facon; H Goldschmidt; JL Harousseau; U Hess; M Kropff; FL da Costa; V Louw; H Magen-Nativ; L Mendeleeva; H Nahi; T Plesner; J San-Miguel; Pieter Sonneveld; M Udvardy; P Sondergeld; AA Palumbo

doi:10.1634/theoncologist.2010-0386

Multiple Myeloma Treatment Strategies with Novel Agents in 2011: A European Perspective

H Ludwig, M Beksac, J Blade, J Cavenagh, M Cavo, M Delforge, M Dimopoulos, J Drach, H Einsele, T Facon, H Goldschmidt, JL Harousseau, U Hess, M Kropff, FL da Costa, V Louw, H Magen-Nativ, L Mendeleeva, H Nahi, T PlesnerJ San-Miguel, Pieter Sonneveld, M Udvardy, P Sondergeld, AA Palumbo

Research output: Contribution to journal › Article › Academic

32 Citations (Scopus)

Abstract

The arrival of the novel agents thalidomide, bortezomib, and lenalidomide has significantly changed our approach to the management of multiple myeloma and, importantly, patient outcomes have improved. These agents have been investigated intensively in different treatment settings, providing us with data to make evidence-based decisions regarding the optimal management of patients. This review is an update to a previous summary of European treatment practices that examines new data that have been published or presented at congresses up to the end of 2010 and assesses their impact on treatment practices. The Oncologist 2011;16:388-403

Original language	Undefined/Unknown
Pages (from-to)	388-403
Number of pages	16
Journal	Oncologist
Volume	16
Issue number	4
DOIs	https://doi.org/10.1634/theoncologist.2010-0386
Publication status	Published - 2011

Research programs

EMC MM-02-41-03

Access to Document

10.1634/theoncologist.2010-0386

http://hdl.handle.net/1765/34207

Cite this

Ludwig, H., Beksac, M., Blade, J., Cavenagh, J., Cavo, M., Delforge, M., Dimopoulos, M., Drach, J., Einsele, H., Facon, T., Goldschmidt, H., Harousseau, JL., Hess, U., Kropff, M., da Costa, FL., Louw, V., Magen-Nativ, H., Mendeleeva, L., Nahi, H., ... Palumbo, AA. (2011). Multiple Myeloma Treatment Strategies with Novel Agents in 2011: A European Perspective. Oncologist, 16(4), 388-403. https://doi.org/10.1634/theoncologist.2010-0386

@article{fb13208bfc2047c1bd247273cb01f03f,

title = "Multiple Myeloma Treatment Strategies with Novel Agents in 2011: A European Perspective",

abstract = "The arrival of the novel agents thalidomide, bortezomib, and lenalidomide has significantly changed our approach to the management of multiple myeloma and, importantly, patient outcomes have improved. These agents have been investigated intensively in different treatment settings, providing us with data to make evidence-based decisions regarding the optimal management of patients. This review is an update to a previous summary of European treatment practices that examines new data that have been published or presented at congresses up to the end of 2010 and assesses their impact on treatment practices. The Oncologist 2011;16:388-403",

author = "H Ludwig and M Beksac and J Blade and J Cavenagh and M Cavo and M Delforge and M Dimopoulos and J Drach and H Einsele and T Facon and H Goldschmidt and JL Harousseau and U Hess and M Kropff and {da Costa}, FL and V Louw and H Magen-Nativ and L Mendeleeva and H Nahi and T Plesner and J San-Miguel and Pieter Sonneveld and M Udvardy and P Sondergeld and AA Palumbo",

year = "2011",

doi = "10.1634/theoncologist.2010-0386",

language = "Undefined/Unknown",

volume = "16",

pages = "388--403",

journal = "Oncologist",

issn = "1083-7159",

publisher = "AlphaMed Press",

number = "4",

}

Ludwig, H, Beksac, M, Blade, J, Cavenagh, J, Cavo, M, Delforge, M, Dimopoulos, M, Drach, J, Einsele, H, Facon, T, Goldschmidt, H, Harousseau, JL, Hess, U, Kropff, M, da Costa, FL, Louw, V, Magen-Nativ, H, Mendeleeva, L, Nahi, H, Plesner, T, San-Miguel, J, Sonneveld, P, Udvardy, M, Sondergeld, P & Palumbo, AA 2011, 'Multiple Myeloma Treatment Strategies with Novel Agents in 2011: A European Perspective', Oncologist, vol. 16, no. 4, pp. 388-403. https://doi.org/10.1634/theoncologist.2010-0386

TY - JOUR

T1 - Multiple Myeloma Treatment Strategies with Novel Agents in 2011: A European Perspective

AU - Ludwig, H

AU - Beksac, M

AU - Blade, J

AU - Cavenagh, J

AU - Cavo, M

AU - Delforge, M

AU - Dimopoulos, M

AU - Drach, J

AU - Einsele, H

AU - Facon, T

AU - Goldschmidt, H

AU - Harousseau, JL

AU - Hess, U

AU - Kropff, M

AU - da Costa, FL

AU - Louw, V

AU - Magen-Nativ, H

AU - Mendeleeva, L

AU - Nahi, H

AU - Plesner, T

AU - San-Miguel, J

AU - Sonneveld, Pieter

AU - Udvardy, M

AU - Sondergeld, P

AU - Palumbo, AA

PY - 2011

Y1 - 2011

N2 - The arrival of the novel agents thalidomide, bortezomib, and lenalidomide has significantly changed our approach to the management of multiple myeloma and, importantly, patient outcomes have improved. These agents have been investigated intensively in different treatment settings, providing us with data to make evidence-based decisions regarding the optimal management of patients. This review is an update to a previous summary of European treatment practices that examines new data that have been published or presented at congresses up to the end of 2010 and assesses their impact on treatment practices. The Oncologist 2011;16:388-403

AB - The arrival of the novel agents thalidomide, bortezomib, and lenalidomide has significantly changed our approach to the management of multiple myeloma and, importantly, patient outcomes have improved. These agents have been investigated intensively in different treatment settings, providing us with data to make evidence-based decisions regarding the optimal management of patients. This review is an update to a previous summary of European treatment practices that examines new data that have been published or presented at congresses up to the end of 2010 and assesses their impact on treatment practices. The Oncologist 2011;16:388-403

U2 - 10.1634/theoncologist.2010-0386

DO - 10.1634/theoncologist.2010-0386

M3 - Article

C2 - 21441574

SN - 1083-7159

VL - 16

SP - 388

EP - 403

JO - Oncologist

JF - Oncologist

IS - 4

ER -